Ghrelin Decreases Insulin Sensitivity

Intravenous Ghrelin Infusion Decreases Insulin Sensitivity in Healthy Young Men

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00512525

Enrollment

Registered

2007-08-07

Start date

2003-01-31

Completion date

2003-10-31

Last updated

2009-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

Ghrelin administration increases appetite and, in rodents, induces weight gain. The aim of this study is to investigate the effect of short term ghrelin administration to humans on metabolism.

Detailed description

The current study is initiated in order to assess the impact of acute ghrelin administration on insulin resistance measured by a hyperinsulinemic euglycemic clamp. Second, as free fatty acid is the predominant substrate during fasting, we aim to asses the effects of ghrelin on local and systemic lipolysis.

Interventions

DRUGGhrelin and saline (as placebo)

Intravenous infusion

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy men, age \>= 18 yr age \< 50 yr, body mass index \< 27.5 kg/m2above or equal to 18 yr

Exclusion criteria

* any disease, use of prescribed medication, age \< 18 yr or \>= 50 yr

Design outcomes

Primary

Measure	Time frame
Insulin sensitivity	End of clamp period

Secondary

Measure	Time frame
Effects on lipolysis	End of basal and end og clamp period

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026